NEW DELHI: Strides Pharma Science will seek approval from the Central Drugs Standard Control Organization, India’s drug regulator, to sell the generic version of antiviral drug favipiravir which has shown results in the treatment of covid-19.
The Bengaluru-based drugmaker has already developed and commercialized the antiviral tablets and will export it to three countries from the Gulf Cooperation Council (GCC), as per a press release by the company. “The product is currently being exported to GCC countries to treat patients under their treatment program for Covid-19.
Strides will also immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously," Strides Pharma said